The drug bank data needs to be examined and solutions developed for the extraction of meaningful terms and data regarding indications to help with the AMP/ASCO Tiering evaluation.
Values:
Cancer type (ex. Non-Small Cell Lung Cancer or Microsatellite Instability-High Cancer)
Biomarker, not all indications will have this (ex. Non-Small Cell Lung Cancer (NSCLC); in combination with [pemetrexed] and platinum-based chemotherapy as a first-line treatment for patients with metastatic nonsquamous NSCLC with no EGFR or ALK mutations)
Combination drug (ex. "in combination with carboplatin and paclitaxel as a first-line treatment for patients with metastatic squamous NSCLC")
korikuzma
commented
2 years ago
The drug bank data needs to be examined and solutions developed for the extraction of meaningful terms and data regarding indications to help with the AMP/ASCO Tiering evaluation.
Values: Cancer type (ex. Non-Small Cell Lung Cancer or Microsatellite Instability-High Cancer)
Biomarker, not all indications will have this (ex. Non-Small Cell Lung Cancer (NSCLC); in combination with [pemetrexed] and platinum-based chemotherapy as a first-line treatment for patients with metastatic nonsquamous NSCLC with no EGFR or ALK mutations)
Combination drug (ex. "in combination with carboplatin and paclitaxel as a first-line treatment for patients with metastatic squamous NSCLC")